Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Cue Biopharma's CUE-101 granted Fast Track designation for treatment of NSCC » 08:03
10/04/22
10/04
08:03
10/04/22
08:03
CUE

Cue Biopharma

$2.39 /

+0.17 (+7.66%)

Cue Biopharma announced…

Cue Biopharma announced that the FDA has granted Fast Track designation to CUE-101, its lead clinical drug candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics, for the treatment of patients with human papilloma virus - HPV16+ - recurrent/metastatic head and neck squamous cell carcinoma - R/M HNSCC - as a monotherapy and in combination with Keytruda, or pembrolizumab. Cue anticipates initiating a registrational trial for CUE-101 monotherapy by mid-2023. CUE-101 is currently being evaluated in a Phase 1b trial as a monotherapy for the treatment of second line and beyond patients with HPV16+ R/M HNSCC and as a first-line treatment in a Phase 1 dose escalation and expansion trial in combination with Keytruda for the same patient population.

ShowHide Related Items >><<
CUE Cue Biopharma
$2.39 /

+0.17 (+7.66%)

CUE Cue Biopharma
$2.39 /

+0.17 (+7.66%)

08/24/22 Oppenheimer
Cue Biopharma price target lowered to $10 from $26 at Oppenheimer
03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
CUE Cue Biopharma
$2.39 /

+0.17 (+7.66%)

Over a week ago
Hot Stocks
Cue Biopharma to present at two September scientific conferences » 08:18
09/07/22
09/07
08:18
09/07/22
08:18
CUE

Cue Biopharma

$2.83 /

-0.25 (-8.12%)

Cue Biopharma announced…

Cue Biopharma announced members of their management and scientific teams will participate in two scientific conferences this September, The Promise of Interleukin-2 Therapy September 14-17 in Paris, France and the Next Generation Protein Therapeutics Summit, held in Boston September 28-30. Dr. Levisetti will present an overview of Cue Biopharma's Immuno-STAT platform highlighting data from clinical trials evaluating CUE-101, the company's lead clinical candidate from the CUE-100 series, in patients with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma as a monotherapy and in combination with pembrolizumab. Dr. Quayle will provide an overview on the company's lead CUE-400 series drug product candidate CUE-401, a novel bispecific molecule designed for differentiation and expansion of induced regulatory T cells. Dr. Quayle will discuss preclinical data supporting CUE-401's mechanism of action and potential opportunity for the treatment of patients with autoimmune and graft-versus-host disease. Cue Biopharma plans to advance the CUE-400 series programs through strategic partnerships. Dr. Suri will present an overview of Cue Biopharma's Immuno-STAT platform and biologics designed to present tumor-specific proteins to T cell receptors of the target tumor-specific T cells, to modulate that T cell repertoire for the anti-cancer response, as well as clinical data demonstrating the single-agent anti-tumor activity of CUE-101, the company's first IL-2 based clinical candidate, in late-stage head and neck cancer patients.

ShowHide Related Items >><<
CUE Cue Biopharma
$2.83 /

-0.25 (-8.12%)

CUE Cue Biopharma
$2.83 /

-0.25 (-8.12%)

08/24/22 Oppenheimer
Cue Biopharma price target lowered to $10 from $26 at Oppenheimer
03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
CUE Cue Biopharma
$2.83 /

-0.25 (-8.12%)

Over a month ago
Recommendations
Cue Biopharma price target lowered to $10 from $26 at Oppenheimer » 06:15
08/24/22
08/24
06:15
08/24/22
06:15
CUE

Cue Biopharma

$3.23 /

+0.19 (+6.26%)

Oppenheimer analyst Mark…

Oppenheimer analyst Mark Breidenbach lowered the firm's price target on Cue Biopharma to $10 from $26 and keeps an Outperform rating on the shares after the company hosted a conference call to review Q2 earnings and discuss recent progress. Management suggested single-agent CUE-101 could potentially enter a pivotal trial in late-line HNSCC by year-end 2023 - later than the analyst had previously anticipated. In his view, a continuing lack of clarity on registrational requirements adds risk to the story, and Breidenbach has updated his model accordingly. Further, the analyst believes early data from an ongoing combination trial of pembro + CUE-101 have yet to highlight any major advantages over single-agent pembro in a 1L, checkpoint-naive HNSCC setting.

ShowHide Related Items >><<
CUE Cue Biopharma
$3.23 /

+0.19 (+6.26%)

CUE Cue Biopharma
$3.23 /

+0.19 (+6.26%)

03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy
CUE Cue Biopharma
$3.23 /

+0.19 (+6.26%)

Conference/Events
Cue Biopharma to host business news update conference call » 16:15
08/23/22
08/23
16:15
08/23/22
16:15
CUE

Cue Biopharma

$3.23 /

+0.19 (+6.26%)

Business news update…

Business news update conference call to be held on August 23 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
CUE Cue Biopharma
$3.23 /

+0.19 (+6.26%)

CUE Cue Biopharma
$3.23 /

+0.19 (+6.26%)

03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy
CUE Cue Biopharma
$3.23 /

+0.19 (+6.26%)

Conference/Events
Cue Biopharma to host business news update conference call » 10:53
08/23/22
08/23
10:53
08/23/22
10:53
CUE

Cue Biopharma

$3.17 /

+0.135 (+4.45%)

Business news update…

Business news update conference call to be held on August 23 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
CUE Cue Biopharma
$3.17 /

+0.135 (+4.45%)

CUE Cue Biopharma
$3.17 /

+0.135 (+4.45%)

03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy
CUE Cue Biopharma
$3.17 /

+0.135 (+4.45%)

Hot Stocks
Cue Biopharma doses 1st patient in CUE-102 study for Wilms' Tumor cancer » 08:29
08/22/22
08/22
08:29
08/22/22
08:29
CUE

Cue Biopharma

$3.04 /

-0.07 (-2.25%)

Cue Biopharma announced …

Cue Biopharma announced that it has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102, its second clinical drug candidate from the CUE-100 series of interleukin 2 based biologics, as a monotherapy for the treatment of patients with Wilms' Tumor 1 -positive recurrent/metastatic cancers. The study will initially focus on colorectal, gastric, pancreatic, and ovarian cancers. "Initiating this Phase 1 clinical study of CUE-102 at a starting dose of 1mg/kg, a clinically active dose in our Phase 1 CUE-101 clinical trial for HPV+ head and neck cancer, is an important step forward in demonstrating the modularity of our Immuno-STAT( platform and the broader clinical potential of our CUE-100 series of biologics," said Dan Passeri, chief executive officer of Cue Biopharma. "We believe, given the preservation of the core molecular framework between CUE-102 and CUE-101 with the primary exception of the tumor-specific epitope, initiating the dose escalation trial at 1 mg/kg will result in reduced time and cost to evaluate tolerability at therapeutically active doses."

ShowHide Related Items >><<
CUE Cue Biopharma
$3.04 /

-0.07 (-2.25%)

CUE Cue Biopharma
$3.04 /

-0.07 (-2.25%)

03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy
CUE Cue Biopharma
$3.04 /

-0.07 (-2.25%)

Over a quarter ago
Hot Stocks
Cue Biopharma to present interim data on CUE-101 in head and neck cancer » 18:17
05/26/22
05/26
18:17
05/26/22
18:17
CUE

Cue Biopharma

$3.58 /

-0.075 (-2.05%)

Cue Biopharma will give a…

Cue Biopharma will give a poster presentation at the ASCO Annual Meeting presenting interim clinical data supporting the tolerability and antitumor activity of Cue Biopharma's lead interleukin 2-based CUE-100 series therapeutic, CUE-101, both as a monotherapy and in combination with pembrolizumab - Keytruda - for the treatment of patients with recurrent/metastatic HPV16+ head and neck cancer.

ShowHide Related Items >><<
CUE Cue Biopharma
$3.58 /

-0.075 (-2.05%)

CUE Cue Biopharma
$3.58 /

-0.075 (-2.05%)

03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy
CUE Cue Biopharma
$3.58 /

-0.075 (-2.05%)

Hot Stocks
Cue Biopharma director buys $711.7K in common stock » 09:26
05/25/22
05/25
09:26
05/25/22
09:26
CUE

Cue Biopharma

$3.33 /

-0.235 (-6.60%)

In a regulatory filing,…

In a regulatory filing, Cue Biopharma disclosed that its director Aaron Fletcher bought 205K shares of common stock on May 23rd in a total transaction size of $711.7K. Shares of Cue Biopharma are up 6% at $3.53 in pre-market trading.

ShowHide Related Items >><<
CUE Cue Biopharma
$3.33 /

-0.235 (-6.60%)

CUE Cue Biopharma
$3.33 /

-0.235 (-6.60%)

03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy
CUE Cue Biopharma
$3.33 /

-0.235 (-6.60%)

Hot Stocks
Cue Biopharma receives FDA acceptance of IND application for CUE-102 » 08:15
05/11/22
05/11
08:15
05/11/22
08:15
CUE

Cue Biopharma

$4.21 /

+0.195 (+4.86%)

Cue Biopharma announced…

Cue Biopharma announced that the U.S. Food and Drug Administration, FDA, has accepted the Company's Investigational New Drug, IND, application for the evaluation of CUE-102, its second interleukin 2, IL-2,-based CUE-100 series biologic, in a dose escalation and expansion monotherapy Phase 1 trial, which will have a starting dose of 1 mg/kg for the treatment of Wilms' Tumor 1-positive recurrent/metastatic cancers, with initial focus on gastric, pancreatic, ovarian and colon cancers. The IND acceptance allowing the dose escalation trial to begin dosing at 1 mg/kg was supported by the safety and tolerability data from the CUE-101 trial. CUE-101, the first biologic from the CUE-100 series, had a starting dose of 0.06 mg/kg and required approximately 9 months to dose escalate from 0.06 mg/kg to 1 mg/kg. "The ability to start our dose escalation trial at 1 mg/kg, is significant as it allows us to initiate the trial at a dose level that demonstrated signs of clinical activity in our CUE-101 trial. At this dose level, we can potentially determine tolerability and therapeutically effective doses much more efficiently by truncating the dose escalation process," stated Ken Pienta, M.D., acting chief medical officer of Cue Biopharma.

ShowHide Related Items >><<
CUE Cue Biopharma
$4.21 /

+0.195 (+4.86%)

CUE Cue Biopharma
$4.21 /

+0.195 (+4.86%)

03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy
CUE Cue Biopharma
$4.21 /

+0.195 (+4.86%)

Earnings
Cue Biopharma reports Q1 EPS (44c), consensus (43c) » 16:39
05/10/22
05/10
16:39
05/10/22
16:39
CUE

Cue Biopharma

$4.21 /

+0.195 (+4.86%)

Reports Q1 revenue $1M,…

Reports Q1 revenue $1M, consensus $3.05M. Through a focused and strategic deployment of resources during the first quarter of 2022, we have made significant progress advancing the IL-2-based CUE-100 series for oncology, as well as strengthening our financial position," said Daniel Passeri, CEO of Cue Biopharma. "As reported, we recently completed the patient expansion phase of the monotherapy Phase 1b clinical trial of CUE-101 and the dose escalation phase of the CUE-101 Phase 1 combination trial with KEYTRUDA. We are very pleased with our clinical trial progress to date and have enhanced confidence in the emerging data supporting the potential of our CUE-100 series pipeline in immuno-oncology through targeted and selective stimulation of the patient's immune system against cancer."

ShowHide Related Items >><<
CUE Cue Biopharma
$4.21 /

+0.195 (+4.86%)

CUE Cue Biopharma
$4.21 /

+0.195 (+4.86%)

03/23/22 JMP Securities
Cue Biopharma price target lowered to $15 from $30 at JMP Securities
03/21/22 Oppenheimer
Cue Biopharma price target lowered to $26 from $32 at Oppenheimer
03/18/22 Craig-Hallum
Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum
01/03/22 Craig-Hallum
Craig-Hallum bullish on Cue Biopharma, initiates with a Buy

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.